Analyst Price Targets — SANA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 1:04 pm | Martin Fan | Wedbush | $7.00 | $3.64 | TheFly | Sana Biotechnology price target raised to $7 from $6 at Wedbush |
| March 13, 2026 5:05 pm | Maxwell Skor | Morgan Stanley | $12.00 | $3.36 | StreetInsider | Morgan Stanley Reiterates Overweight Rating on Sana Biotechnology (SANA) after "meaningful platform level de-risking event" |
| March 4, 2026 11:41 am | Emily Bodnar | H.C. Wainwright | $7.00 | $3.85 | StreetInsider | Sana Biotechnology (SANA) PT Lowered to $7 at H.C. Wainwright |
| October 30, 2025 10:23 am | — | JMP Securities | $8.00 | $5.37 | TheFly | Sana Biotechnology price target raised to $8 from $5 at Citizens JMP |
| November 5, 2024 11:41 am | Emily Bodnar | H.C. Wainwright | $8.00 | $3.39 | StreetInsider | Sana Biotechnology (SANA) PT Lowered to $8 at H.C. Wainwright |
| January 16, 2024 6:05 am | Emily Bodnar | H.C. Wainwright | $12.00 | $6.36 | StreetInsider | H.C. Wainwright Upgrades Sana Biotechnology (SANA) to Buy |
Latest News for SANA
Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune platform (HIP) technology, into a…
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SANA.
U.S. House Trading
No House trades found for SANA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.